It's possible Phase II will be designed and enrollment begun prior to year end.
Taking this momentum into account, with an accompanying sp re-rate higher, a PP (if needed) to pay for Phase II would be another welcome entry point for me.
The study's endpoints, in my mind, are easily established and measured. First, don't kill the patient. Second, measure the DFU before treatment, then after. Third, once efficacy proven, repeat on a larger scale. Fourth, commercialize.
Fundamentals like funding, JVs, T/Os, competition, even inrigue may swirl around CYP... I think it will be a good ride... (Hint: 87.6% v 51.1 wound reduction CYP v control))
OV
***
*****
It's possible Phase II will be designed and enrollment begun...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
-0.005(2.78%) |
Mkt cap ! $39.54M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $6.287K | 35.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 67866 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 27766 | 2 |
View Market Depth
| Last trade - 11.42am 29/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |